Another-1 Immortalizes Street Art and Streetwear with ‘Drip-Lab’ - combining NFTs, PFPs and NFC Technology
20.7.2023 15:00:00 EEST | Business Wire | Press release
Another-1, the web3 luxury fashion platform, today announces the global launch of Drip-Lab – a multi-faceted phygital NFT project in collaboration with Como-based luxury technical fabric mill Olmetex, and renowned graffiti writer and artist Zoow24.
Drip-Lab launches with a mission to define the global intersection of art, graffiti, technology and streetwear, uniting a new and vibrant community of collectors and connoisseurs in the process. By launching a graffiti and street-culture inspired NFT collection, immortalizing Zoow24’s “The Wall” mural as an NFT, as well as linking the artist’s iconic illustrated characters to an NFC-enabled Olmetex fabricated windbreaker jacket, every aspect of the Drip-Lab project combines to ensure that historically ephemeral street art can be recorded, owned and flexed forever.
At the heart of this project are Zoow24’s five instantly recognisable ‘miniature behemoth’ monster character NFTs - REKT, EXTO, KULT, CRYMELON, and ROOT - which represent vices that can cause an artist to lose their way. The NFTs will be available with over 1,700 backgrounds, 183 monster traits, and 5,555 profile pictures (PFPs) variations as the Drip-Lab community grows.
In short, this unique blend of physical and digital (phygital) utility offers ‘Drip-Lab’ holders around the world the chance to flex a range of digital PFPs, physical products and murals, as well as augmented reality experiences that will be revealed with Another-1’s plans for future activations.
The ‘Drip-Lab’ Roadmap
The Pre-mint for ‘Drip-Lab’ is now live in anticipation of the sale on the Another-1 ADO Launchpad, allowing interested community members exclusive access to mint this project by linking their wallet ahead of the public offering.
Next week, on Wednesday, July 26th at 1pm EDT / 5pm UTC, presale for the project opens, and on July 27th at 1pm EDT / 5pm UTC the public sale will go live. An individual PFP will cost $150 USD each and to forge a customized jacket will cost $350 USD. After the drop, added benefits and utilities will be revealed as holders of these PFP project NFTs will benefit from a free airdrop of an NFT that immortalizes ‘The Wall’ art created by Zoow24 in Como. Adding the fashion and streetwear element, a highly anticipated aspect of this project is a limited edition windbreaker jacket that comes equipped with Near Field Communication (NFC) technology.
Designed by Olmetex, a world-renowned Italian mill setting the standard for fashion’s leading technical fabrics, these jackets showcase five captivating thermo-reactive dual-colorways and feature ZOOW24’s monsters on the inside lining for a customized finish.
Apart from making sure its wearer looks good in the streets, ‘The Writer’s Jacket’ will enable its owners’ to take advantage of Another-1’s ‘Flex-To-Earn’ module and get a 25% cash back airdrop in $AN1 tokens once the collection sales have been concluded, and the NFT redeem for the physical Jacket will be available later this year.
Speaking on the project, artist Zoow24 said, “Drip-Lab is a cautionary expose of what vices become when they spiral out of control. When you stop doing the drugs and the drugs do you. Habits are what make us human and how we choose to spend our time defines us as people.” “As a whole, this collaboration with Another-1 and Olmetex has created an opportunity for me to take my art, my characters and my creativity to a whole range of platforms and possibilities.”
Marco Staglianò, CEO of Another-1, added, “Our mission is to push the envelope and radically change the way art is produced and traded. By establishing the Drip-Lab project along with Olmetex and renowned artists such as Zoow24, we are proving that graffiti is a medium that can live on and be appreciated forever. This is a historical crossover of art, fashion, and groundbreaking technology and we’re excited for what’s still to come.”
“Working with a renowned fabric manufacturer like Olmetex, we also have the opportunity to tie physical fashion to this story of street and digital art. This is a first for the world and we’re excited to see how these passionate communities of street art and streetwear collectors will respond.”
Finally, Olmetex Managing Director, Beatrice Breschi had this to say: “Olmetex has decided to make the facade of its textile company available to graffiti artists, because it has always believed in the close union between fashion and art. This approach is a source of inspiration for our customers, which has always been part of our spirit and characteristics: elasticity, flexibility and constant openness to new ideas and challenges that the market offers. With these NFTs and the physical redemption of the waterproof jacket produced with its own fabrics, Olmetex sets itself the goal of making an art project tangible and fashionable.
“We’re excited to see our near-70 year old Mill involved in a web3 project that creates a new and important way to enjoy art and fashion. We have always been future-focused with our fabric innovation, and now we are taking this mindset to a collaboration that takes fashion, art and fabric into the next decade.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720752001/en/
Contact information
Bridget van Voorst
bridget@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
